CN103585224B - 一种阿尔泰狗娃花提取物在制备治疗白血病药物中的应用 - Google Patents
一种阿尔泰狗娃花提取物在制备治疗白血病药物中的应用 Download PDFInfo
- Publication number
- CN103585224B CN103585224B CN201310525577.XA CN201310525577A CN103585224B CN 103585224 B CN103585224 B CN 103585224B CN 201310525577 A CN201310525577 A CN 201310525577A CN 103585224 B CN103585224 B CN 103585224B
- Authority
- CN
- China
- Prior art keywords
- thunb
- hispidus
- less
- extract
- aster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000442277 Aster hispidus Species 0.000 title claims abstract description 189
- 239000000284 extract Substances 0.000 title claims abstract description 146
- 208000032839 leukemia Diseases 0.000 title claims abstract description 51
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000000341 volatile oil Substances 0.000 claims abstract description 19
- 239000011347 resin Substances 0.000 claims abstract description 18
- 229920005989 resin Polymers 0.000 claims abstract description 18
- 238000000605 extraction Methods 0.000 claims description 54
- 239000007788 liquid Substances 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000003463 adsorbent Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 10
- 230000001476 alcoholic effect Effects 0.000 claims description 9
- 239000006286 aqueous extract Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 238000001256 steam distillation Methods 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 8
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 7
- 229960001330 hydroxycarbamide Drugs 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 206010008583 Chloroma Diseases 0.000 description 5
- 201000005987 myeloid sarcoma Diseases 0.000 description 5
- 230000001332 colony forming effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 3
- 244000192528 Chrysanthemum parthenium Species 0.000 description 3
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000008384 feverfew Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002607 hemopoietic effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 241000435900 Aster altaicus Species 0.000 description 2
- 241000131317 Capitulum Species 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- -1 dry Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 208000008286 Aortic Arch Syndromes Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- HAVJATCHLFRDHY-UHFFFAOYSA-N Harringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HAVJATCHLFRDHY-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010058483 Nuchal rigidity Diseases 0.000 description 1
- 241000278080 Picris japonica Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026915 cervical aortic arch Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- HAVJATCHLFRDHY-JZTSUELASA-N harringtonine Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@](O)(CCC(C)(C)O)CC(=O)OC)[C@@H]4C2=CC2=C1OCO2 HAVJATCHLFRDHY-JZTSUELASA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310525577.XA CN103585224B (zh) | 2013-10-31 | 2013-10-31 | 一种阿尔泰狗娃花提取物在制备治疗白血病药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310525577.XA CN103585224B (zh) | 2013-10-31 | 2013-10-31 | 一种阿尔泰狗娃花提取物在制备治疗白血病药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103585224A CN103585224A (zh) | 2014-02-19 |
CN103585224B true CN103585224B (zh) | 2015-10-28 |
Family
ID=50075678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310525577.XA Expired - Fee Related CN103585224B (zh) | 2013-10-31 | 2013-10-31 | 一种阿尔泰狗娃花提取物在制备治疗白血病药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103585224B (zh) |
-
2013
- 2013-10-31 CN CN201310525577.XA patent/CN103585224B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103585224A (zh) | 2014-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103768534B (zh) | 一种具有抗肿瘤活性的中药组合物 | |
JP6538282B2 (ja) | 白血病治療用医薬組成物及びその製造方法 | |
CN103585227B (zh) | 一种褐毛橐吾提取物在制备治疗白血病药物中的应用 | |
CN103585224B (zh) | 一种阿尔泰狗娃花提取物在制备治疗白血病药物中的应用 | |
JP2005502602A (ja) | ウイルス感染の治療用の医薬組成物 | |
CN103585211B (zh) | 阿莫尼亚脂提取物在制备治疗白血病药物中的应用 | |
CN103585238B (zh) | 一种齿缘草提取物在制备治疗白血病药物中的应用 | |
CN103585193B (zh) | 通经草提取物在制备治疗白血病药物中的应用 | |
CN100345537C (zh) | 汉黄芩素在制备治疗白血病药物中的应用 | |
EP0956860A1 (en) | Hematopoietic function restorative and processed food both containing treated peanut testae | |
CN103169778B (zh) | 一种治疗肺癌的药物组合物及其制备方法 | |
CN103585220B (zh) | 毛莲菜提取物在制备治疗白血病药物中的应用 | |
CN103610734B (zh) | 一种白花油麻藤提取物在制备治疗白血病药物中的应用 | |
CN1850149A (zh) | 一种黄芪提取物与香菇多糖组成的复方制剂及其制备方法 | |
CN113101331B (zh) | 一种百里香药茶及其制备方法和应用 | |
CN110772513B (zh) | 一种治疗白血病的药物 | |
CN109350694B (zh) | 一种具有保健功效中药“全组分”提取物、其制备方法及应用 | |
KR102015858B1 (ko) | 법제된 비상을 함유하는 면역력 증강을 위한 약학적 조성물 | |
CN100484537C (zh) | 一种抗艾滋病病毒的中药提取物 | |
CN107753551B (zh) | 一种具有降血压功能的组合物及其制备方法 | |
CN105267277A (zh) | 一种滨紫草提取物在制备治疗白血病中的应用 | |
CN105311148A (zh) | 一种中药提取物及其在制备治疗白血病中的应用 | |
CN104474227A (zh) | 一种治疗肝炎合并再生障碍性贫血的中药组合物 | |
CN105362664A (zh) | 一种中药组合提取物及其在制备治疗白血病中的应用 | |
JPS61263923A (ja) | インタ−ロイキン−2誘起剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TIAN JUN Free format text: FORMER OWNER: JINAN XINGYI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20150908 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Tian Jun Inventor after: Dong Guangcai Inventor before: Kong Qianqian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: KONG QIANQIAN TO: TIAN JUN DONG GUANGCAI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150908 Address after: 262199 Anqiu people's Hospital, No. 3, building 2, building 259, 305 health Road, Shandong, Weifang Applicant after: Tian Jun Address before: 250101 No. 51 Industrial South Road, Ji'nan hi tech Zone, Shandong, Ji'nan Applicant before: Jinan Xingyi Medical Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151028 Termination date: 20161031 |
|
CF01 | Termination of patent right due to non-payment of annual fee |